

Global Angiogenesis Inhibitors Market Growth 2024-2030

<https://marketpublishers.com/r/G847FC256034EN.html>

Date: July 2024

Pages: 110

Price: US\$ 3,660.00 (Single User License)

ID: G847FC256034EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Angiogenesis inhibitors are unique cancer-fighting agents because they block the growth of blood vessels that support tumor growth rather than blocking the growth of tumor cells themselves. Angiogenesis inhibitors interfere in several ways with various steps in blood vessel growth.

The global Angiogenesis Inhibitors market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Angiogenesis Inhibitors Industry Forecast” looks at past sales and reviews total world Angiogenesis Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected Angiogenesis Inhibitors sales for 2024 through 2030. With Angiogenesis Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Angiogenesis Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Angiogenesis Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiogenesis Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiogenesis Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiogenesis Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiogenesis Inhibitors.

United States market for Angiogenesis Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Angiogenesis Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Angiogenesis Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Angiogenesis Inhibitors players cover Roche, Pfizer, Exelixis, Novarti, Takeda Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Angiogenesis Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Oral

Injectable

Other

Segmentation by Application:

Kidney Cancer

Lung Cancer

Breast Cancer

Colon Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Pfizer

Exelixis

Novarti

Takeda Pharmaceutical

Melinta Therapeutics

Cipla

Sun Pharmaceutical Industries

Bristol-Myers Squibb

Balaji Medical Services

Eli Lilly

Bayer

Sanofi

Merck & Co

Key Questions Addressed in this Report

What is the 10-year outlook for the global Angiogenesis Inhibitors market?

What factors are driving Angiogenesis Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Angiogenesis Inhibitors market opportunities vary by end market size?

How does Angiogenesis Inhibitors break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Angiogenesis Inhibitors Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Angiogenesis Inhibitors by Country/Region, 2019, 2023 & 2030

2.2 Angiogenesis Inhibitors Segment by Type

- 2.2.1 Oral
- 2.2.2 Injectable
- 2.2.3 Other

2.3 Angiogenesis Inhibitors Sales by Type

- 2.3.1 Global Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)
- 2.3.2 Global Angiogenesis Inhibitors Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Angiogenesis Inhibitors Sale Price by Type (2019-2024)

2.4 Angiogenesis Inhibitors Segment by Application

- 2.4.1 Kidney Cancer
- 2.4.2 Lung Cancer
- 2.4.3 Breast Cancer
- 2.4.4 Colon Cancer
- 2.4.5 Other

2.5 Angiogenesis Inhibitors Sales by Application

- 2.5.1 Global Angiogenesis Inhibitors Sale Market Share by Application (2019-2024)
- 2.5.2 Global Angiogenesis Inhibitors Revenue and Market Share by Application (2019-2024)

2.5.3 Global Angiogenesis Inhibitors Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Angiogenesis Inhibitors Breakdown Data by Company

3.1.1 Global Angiogenesis Inhibitors Annual Sales by Company (2019-2024)

3.1.2 Global Angiogenesis Inhibitors Sales Market Share by Company (2019-2024)

3.2 Global Angiogenesis Inhibitors Annual Revenue by Company (2019-2024)

3.2.1 Global Angiogenesis Inhibitors Revenue by Company (2019-2024)

3.2.2 Global Angiogenesis Inhibitors Revenue Market Share by Company (2019-2024)

3.3 Global Angiogenesis Inhibitors Sale Price by Company

3.4 Key Manufacturers Angiogenesis Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Angiogenesis Inhibitors Product Location Distribution

3.4.2 Players Angiogenesis Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ANGIOGENESIS INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Angiogenesis Inhibitors Market Size by Geographic Region (2019-2024)

4.1.1 Global Angiogenesis Inhibitors Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Angiogenesis Inhibitors Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Angiogenesis Inhibitors Market Size by Country/Region (2019-2024)

4.2.1 Global Angiogenesis Inhibitors Annual Sales by Country/Region (2019-2024)

4.2.2 Global Angiogenesis Inhibitors Annual Revenue by Country/Region (2019-2024)

4.3 Americas Angiogenesis Inhibitors Sales Growth

4.4 APAC Angiogenesis Inhibitors Sales Growth

4.5 Europe Angiogenesis Inhibitors Sales Growth

4.6 Middle East & Africa Angiogenesis Inhibitors Sales Growth

5 AMERICAS

5.1 Americas Angiogenesis Inhibitors Sales by Country

5.1.1 Americas Angiogenesis Inhibitors Sales by Country (2019-2024)

5.1.2 Americas Angiogenesis Inhibitors Revenue by Country (2019-2024)

5.2 Americas Angiogenesis Inhibitors Sales by Type (2019-2024)

5.3 Americas Angiogenesis Inhibitors Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Angiogenesis Inhibitors Sales by Region

6.1.1 APAC Angiogenesis Inhibitors Sales by Region (2019-2024)

6.1.2 APAC Angiogenesis Inhibitors Revenue by Region (2019-2024)

6.2 APAC Angiogenesis Inhibitors Sales by Type (2019-2024)

6.3 APAC Angiogenesis Inhibitors Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Angiogenesis Inhibitors by Country

7.1.1 Europe Angiogenesis Inhibitors Sales by Country (2019-2024)

7.1.2 Europe Angiogenesis Inhibitors Revenue by Country (2019-2024)

7.2 Europe Angiogenesis Inhibitors Sales by Type (2019-2024)

7.3 Europe Angiogenesis Inhibitors Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Angiogenesis Inhibitors by Country

8.1.1 Middle East & Africa Angiogenesis Inhibitors Sales by Country (2019-2024)

8.1.2 Middle East & Africa Angiogenesis Inhibitors Revenue by Country (2019-2024)

8.2 Middle East & Africa Angiogenesis Inhibitors Sales by Type (2019-2024)

8.3 Middle East & Africa Angiogenesis Inhibitors Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Angiogenesis Inhibitors

10.3 Manufacturing Process Analysis of Angiogenesis Inhibitors

10.4 Industry Chain Structure of Angiogenesis Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Angiogenesis Inhibitors Distributors

11.3 Angiogenesis Inhibitors Customer

12 WORLD FORECAST REVIEW FOR ANGIOGENESIS INHIBITORS BY GEOGRAPHIC REGION

12.1 Global Angiogenesis Inhibitors Market Size Forecast by Region

12.1.1 Global Angiogenesis Inhibitors Forecast by Region (2025-2030)

12.1.2 Global Angiogenesis Inhibitors Annual Revenue Forecast by Region

(2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Angiogenesis Inhibitors Forecast by Type (2025-2030)

12.7 Global Angiogenesis Inhibitors Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Roche

13.1.1 Roche Company Information

13.1.2 Roche Angiogenesis Inhibitors Product Portfolios and Specifications

13.1.3 Roche Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.1.4 Roche Main Business Overview

13.1.5 Roche Latest Developments

13.2 Pfizer

13.2.1 Pfizer Company Information

13.2.2 Pfizer Angiogenesis Inhibitors Product Portfolios and Specifications

13.2.3 Pfizer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.2.4 Pfizer Main Business Overview

13.2.5 Pfizer Latest Developments

13.3 Exelixis

13.3.1 Exelixis Company Information

13.3.2 Exelixis Angiogenesis Inhibitors Product Portfolios and Specifications

13.3.3 Exelixis Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.3.4 Exelixis Main Business Overview

13.3.5 Exelixis Latest Developments

13.4 Novartis

13.4.1 Novartis Company Information

13.4.2 Novartis Angiogenesis Inhibitors Product Portfolios and Specifications

13.4.3 Novartis Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.4.4 Novartis Main Business Overview

13.4.5 Novartis Latest Developments

13.5 Takeda Pharmaceutical

- 13.5.1 Takeda Pharmaceutical Company Information
- 13.5.2 Takeda Pharmaceutical Angiogenesis Inhibitors Product Portfolios and Specifications
- 13.5.3 Takeda Pharmaceutical Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.5.4 Takeda Pharmaceutical Main Business Overview
- 13.5.5 Takeda Pharmaceutical Latest Developments
- 13.6 Melinta Therapeutics
 - 13.6.1 Melinta Therapeutics Company Information
 - 13.6.2 Melinta Therapeutics Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.6.3 Melinta Therapeutics Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Melinta Therapeutics Main Business Overview
 - 13.6.5 Melinta Therapeutics Latest Developments
- 13.7 Cipla
 - 13.7.1 Cipla Company Information
 - 13.7.2 Cipla Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.7.3 Cipla Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Cipla Main Business Overview
 - 13.7.5 Cipla Latest Developments
- 13.8 Sun Pharmaceutical Industries
 - 13.8.1 Sun Pharmaceutical Industries Company Information
 - 13.8.2 Sun Pharmaceutical Industries Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.8.3 Sun Pharmaceutical Industries Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 Sun Pharmaceutical Industries Main Business Overview
 - 13.8.5 Sun Pharmaceutical Industries Latest Developments
- 13.9 Bristol-Myers Squibb
 - 13.9.1 Bristol-Myers Squibb Company Information
 - 13.9.2 Bristol-Myers Squibb Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.9.3 Bristol-Myers Squibb Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.9.4 Bristol-Myers Squibb Main Business Overview
 - 13.9.5 Bristol-Myers Squibb Latest Developments
- 13.10 Balaji Medical Services

- 13.10.1 Balaji Medical Services Company Information
- 13.10.2 Balaji Medical Services Angiogenesis Inhibitors Product Portfolios and Specifications
- 13.10.3 Balaji Medical Services Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.10.4 Balaji Medical Services Main Business Overview
- 13.10.5 Balaji Medical Services Latest Developments
- 13.11 Eli Lilly
 - 13.11.1 Eli Lilly Company Information
 - 13.11.2 Eli Lilly Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.11.3 Eli Lilly Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Eli Lilly Main Business Overview
 - 13.11.5 Eli Lilly Latest Developments
- 13.12 Bayer
 - 13.12.1 Bayer Company Information
 - 13.12.2 Bayer Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.12.3 Bayer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Bayer Main Business Overview
 - 13.12.5 Bayer Latest Developments
- 13.13 Sanofi
 - 13.13.1 Sanofi Company Information
 - 13.13.2 Sanofi Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.13.3 Sanofi Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.13.4 Sanofi Main Business Overview
 - 13.13.5 Sanofi Latest Developments
- 13.14 Merck & Co
 - 13.14.1 Merck & Co Company Information
 - 13.14.2 Merck & Co Angiogenesis Inhibitors Product Portfolios and Specifications
 - 13.14.3 Merck & Co Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.14.4 Merck & Co Main Business Overview
 - 13.14.5 Merck & Co Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Angiogenesis Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Angiogenesis Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Oral

Table 4. Major Players of Injectable

Table 5. Major Players of Other

Table 6. Global Angiogenesis Inhibitors Sales by Type (2019-2024) & (K Units)

Table 7. Global Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)

Table 8. Global Angiogenesis Inhibitors Revenue by Type (2019-2024) & (\$ million)

Table 9. Global Angiogenesis Inhibitors Revenue Market Share by Type (2019-2024)

Table 10. Global Angiogenesis Inhibitors Sale Price by Type (2019-2024) & (US\$/Unit)

Table 11. Global Angiogenesis Inhibitors Sale by Application (2019-2024) & (K Units)

Table 12. Global Angiogenesis Inhibitors Sale Market Share by Application (2019-2024)

Table 13. Global Angiogenesis Inhibitors Revenue by Application (2019-2024) & (\$ million)

Table 14. Global Angiogenesis Inhibitors Revenue Market Share by Application (2019-2024)

Table 15. Global Angiogenesis Inhibitors Sale Price by Application (2019-2024) & (US\$/Unit)

Table 16. Global Angiogenesis Inhibitors Sales by Company (2019-2024) & (K Units)

Table 17. Global Angiogenesis Inhibitors Sales Market Share by Company (2019-2024)

Table 18. Global Angiogenesis Inhibitors Revenue by Company (2019-2024) & (\$ millions)

Table 19. Global Angiogenesis Inhibitors Revenue Market Share by Company (2019-2024)

Table 20. Global Angiogenesis Inhibitors Sale Price by Company (2019-2024) & (US\$/Unit)

Table 21. Key Manufacturers Angiogenesis Inhibitors Producing Area Distribution and Sales Area

Table 22. Players Angiogenesis Inhibitors Products Offered

Table 23. Angiogenesis Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Angiogenesis Inhibitors Sales by Geographic Region (2019-2024) & (K Units)

Table 27. Global Angiogenesis Inhibitors Sales Market Share Geographic Region (2019-2024)

Table 28. Global Angiogenesis Inhibitors Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 29. Global Angiogenesis Inhibitors Revenue Market Share by Geographic Region (2019-2024)

Table 30. Global Angiogenesis Inhibitors Sales by Country/Region (2019-2024) & (K Units)

Table 31. Global Angiogenesis Inhibitors Sales Market Share by Country/Region (2019-2024)

Table 32. Global Angiogenesis Inhibitors Revenue by Country/Region (2019-2024) & (\$ millions)

Table 33. Global Angiogenesis Inhibitors Revenue Market Share by Country/Region (2019-2024)

Table 34. Americas Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)

Table 35. Americas Angiogenesis Inhibitors Sales Market Share by Country (2019-2024)

Table 36. Americas Angiogenesis Inhibitors Revenue by Country (2019-2024) & (\$ millions)

Table 37. Americas Angiogenesis Inhibitors Sales by Type (2019-2024) & (K Units)

Table 38. Americas Angiogenesis Inhibitors Sales by Application (2019-2024) & (K Units)

Table 39. APAC Angiogenesis Inhibitors Sales by Region (2019-2024) & (K Units)

Table 40. APAC Angiogenesis Inhibitors Sales Market Share by Region (2019-2024)

Table 41. APAC Angiogenesis Inhibitors Revenue by Region (2019-2024) & (\$ millions)

Table 42. APAC Angiogenesis Inhibitors Sales by Type (2019-2024) & (K Units)

Table 43. APAC Angiogenesis Inhibitors Sales by Application (2019-2024) & (K Units)

Table 44. Europe Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)

Table 45. Europe Angiogenesis Inhibitors Revenue by Country (2019-2024) & (\$ millions)

Table 46. Europe Angiogenesis Inhibitors Sales by Type (2019-2024) & (K Units)

Table 47. Europe Angiogenesis Inhibitors Sales by Application (2019-2024) & (K Units)

Table 48. Middle East & Africa Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)

Table 49. Middle East & Africa Angiogenesis Inhibitors Revenue Market Share by Country (2019-2024)

Table 50. Middle East & Africa Angiogenesis Inhibitors Sales by Type (2019-2024) & (K

Units)

Table 51. Middle East & Africa Angiogenesis Inhibitors Sales by Application (2019-2024) & (K Units)

Table 52. Key Market Drivers & Growth Opportunities of Angiogenesis Inhibitors

Table 53. Key Market Challenges & Risks of Angiogenesis Inhibitors

Table 54. Key Industry Trends of Angiogenesis Inhibitors

Table 55. Angiogenesis Inhibitors Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Angiogenesis Inhibitors Distributors List

Table 58. Angiogenesis Inhibitors Customer List

Table 59. Global Angiogenesis Inhibitors Sales Forecast by Region (2025-2030) & (K Units)

Table 60. Global Angiogenesis Inhibitors Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 61. Americas Angiogenesis Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 62. Americas Angiogenesis Inhibitors Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 63. APAC Angiogenesis Inhibitors Sales Forecast by Region (2025-2030) & (K Units)

Table 64. APAC Angiogenesis Inhibitors Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 65. Europe Angiogenesis Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 66. Europe Angiogenesis Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 67. Middle East & Africa Angiogenesis Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 68. Middle East & Africa Angiogenesis Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 69. Global Angiogenesis Inhibitors Sales Forecast by Type (2025-2030) & (K Units)

Table 70. Global Angiogenesis Inhibitors Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 71. Global Angiogenesis Inhibitors Sales Forecast by Application (2025-2030) & (K Units)

Table 72. Global Angiogenesis Inhibitors Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 73. Roche Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales

Area and Its Competitors

Table 74. Roche Angiogenesis Inhibitors Product Portfolios and Specifications

Table 75. Roche Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 76. Roche Main Business

Table 77. Roche Latest Developments

Table 78. Pfizer Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 79. Pfizer Angiogenesis Inhibitors Product Portfolios and Specifications

Table 80. Pfizer Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 81. Pfizer Main Business

Table 82. Pfizer Latest Developments

Table 83. Exelixis Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 84. Exelixis Angiogenesis Inhibitors Product Portfolios and Specifications

Table 85. Exelixis Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 86. Exelixis Main Business

Table 87. Exelixis Latest Developments

Table 88. Novartis Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 89. Novartis Angiogenesis Inhibitors Product Portfolios and Specifications

Table 90. Novartis Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 91. Novartis Main Business

Table 92. Novartis Latest Developments

Table 93. Takeda Pharmaceutical Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 94. Takeda Pharmaceutical Angiogenesis Inhibitors Product Portfolios and Specifications

Table 95. Takeda Pharmaceutical Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 96. Takeda Pharmaceutical Main Business

Table 97. Takeda Pharmaceutical Latest Developments

Table 98. Melinta Therapeutics Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 99. Melinta Therapeutics Angiogenesis Inhibitors Product Portfolios and Specifications

Table 100. Melinta Therapeutics Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 101. Melinta Therapeutics Main Business

Table 102. Melinta Therapeutics Latest Developments

Table 103. Cipla Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 104. Cipla Angiogenesis Inhibitors Product Portfolios and Specifications

Table 105. Cipla Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 106. Cipla Main Business

Table 107. Cipla Latest Developments

Table 108. Sun Pharmaceutical Industries Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 109. Sun Pharmaceutical Industries Angiogenesis Inhibitors Product Portfolios and Specifications

Table 110. Sun Pharmaceutical Industries Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 111. Sun Pharmaceutical Industries Main Business

Table 112. Sun Pharmaceutical Industries Latest Developments

Table 113. Bristol-Myers Squibb Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 114. Bristol-Myers Squibb Angiogenesis Inhibitors Product Portfolios and Specifications

Table 115. Bristol-Myers Squibb Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 116. Bristol-Myers Squibb Main Business

Table 117. Bristol-Myers Squibb Latest Developments

Table 118. Balaji Medical Services Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 119. Balaji Medical Services Angiogenesis Inhibitors Product Portfolios and Specifications

Table 120. Balaji Medical Services Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 121. Balaji Medical Services Main Business

Table 122. Balaji Medical Services Latest Developments

Table 123. Eli Lilly Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 124. Eli Lilly Angiogenesis Inhibitors Product Portfolios and Specifications

Table 125. Eli Lilly Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price

(US\$/Unit) and Gross Margin (2019-2024)

Table 126. Eli Lilly Main Business

Table 127. Eli Lilly Latest Developments

Table 128. Bayer Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 129. Bayer Angiogenesis Inhibitors Product Portfolios and Specifications

Table 130. Bayer Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 131. Bayer Main Business

Table 132. Bayer Latest Developments

Table 133. Sanofi Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 134. Sanofi Angiogenesis Inhibitors Product Portfolios and Specifications

Table 135. Sanofi Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 136. Sanofi Main Business

Table 137. Sanofi Latest Developments

Table 138. Merck & Co Basic Information, Angiogenesis Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 139. Merck & Co Angiogenesis Inhibitors Product Portfolios and Specifications

Table 140. Merck & Co Angiogenesis Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 141. Merck & Co Main Business

Table 142. Merck & Co Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Angiogenesis Inhibitors
- Figure 2. Angiogenesis Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Angiogenesis Inhibitors Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Angiogenesis Inhibitors Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Angiogenesis Inhibitors Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Angiogenesis Inhibitors Sales Market Share by Country/Region (2023)
- Figure 10. Angiogenesis Inhibitors Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Oral
- Figure 12. Product Picture of Injectable
- Figure 13. Product Picture of Other
- Figure 14. Global Angiogenesis Inhibitors Sales Market Share by Type in 2023
- Figure 15. Global Angiogenesis Inhibitors Revenue Market Share by Type (2019-2024)
- Figure 16. Angiogenesis Inhibitors Consumed in Kidney Cancer
- Figure 17. Global Angiogenesis Inhibitors Market: Kidney Cancer (2019-2024) & (K Units)
- Figure 18. Angiogenesis Inhibitors Consumed in Lung Cancer
- Figure 19. Global Angiogenesis Inhibitors Market: Lung Cancer (2019-2024) & (K Units)
- Figure 20. Angiogenesis Inhibitors Consumed in Breast Cancer
- Figure 21. Global Angiogenesis Inhibitors Market: Breast Cancer (2019-2024) & (K Units)
- Figure 22. Angiogenesis Inhibitors Consumed in Colon Cancer
- Figure 23. Global Angiogenesis Inhibitors Market: Colon Cancer (2019-2024) & (K Units)
- Figure 24. Angiogenesis Inhibitors Consumed in Other
- Figure 25. Global Angiogenesis Inhibitors Market: Other (2019-2024) & (K Units)
- Figure 26. Global Angiogenesis Inhibitors Sale Market Share by Application (2023)
- Figure 27. Global Angiogenesis Inhibitors Revenue Market Share by Application in 2023
- Figure 28. Angiogenesis Inhibitors Sales by Company in 2023 (K Units)
- Figure 29. Global Angiogenesis Inhibitors Sales Market Share by Company in 2023
- Figure 30. Angiogenesis Inhibitors Revenue by Company in 2023 (\$ millions)

- Figure 31. Global Angiogenesis Inhibitors Revenue Market Share by Company in 2023
- Figure 32. Global Angiogenesis Inhibitors Sales Market Share by Geographic Region (2019-2024)
- Figure 33. Global Angiogenesis Inhibitors Revenue Market Share by Geographic Region in 2023
- Figure 34. Americas Angiogenesis Inhibitors Sales 2019-2024 (K Units)
- Figure 35. Americas Angiogenesis Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 36. APAC Angiogenesis Inhibitors Sales 2019-2024 (K Units)
- Figure 37. APAC Angiogenesis Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 38. Europe Angiogenesis Inhibitors Sales 2019-2024 (K Units)
- Figure 39. Europe Angiogenesis Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 40. Middle East & Africa Angiogenesis Inhibitors Sales 2019-2024 (K Units)
- Figure 41. Middle East & Africa Angiogenesis Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 42. Americas Angiogenesis Inhibitors Sales Market Share by Country in 2023
- Figure 43. Americas Angiogenesis Inhibitors Revenue Market Share by Country (2019-2024)
- Figure 44. Americas Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)
- Figure 45. Americas Angiogenesis Inhibitors Sales Market Share by Application (2019-2024)
- Figure 46. United States Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 47. Canada Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 48. Mexico Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 49. Brazil Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 50. APAC Angiogenesis Inhibitors Sales Market Share by Region in 2023
- Figure 51. APAC Angiogenesis Inhibitors Revenue Market Share by Region (2019-2024)
- Figure 52. APAC Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)
- Figure 53. APAC Angiogenesis Inhibitors Sales Market Share by Application (2019-2024)
- Figure 54. China Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 55. Japan Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 56. South Korea Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 57. Southeast Asia Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 58. India Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 59. Australia Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 60. China Taiwan Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 61. Europe Angiogenesis Inhibitors Sales Market Share by Country in 2023

Figure 62. Europe Angiogenesis Inhibitors Revenue Market Share by Country (2019-2024)

Figure 63. Europe Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)

Figure 64. Europe Angiogenesis Inhibitors Sales Market Share by Application (2019-2024)

Figure 65. Germany Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 66. France Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 67. UK Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 68. Italy Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 69. Russia Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 70. Middle East & Africa Angiogenesis Inhibitors Sales Market Share by Country (2019-2024)

Figure 71. Middle East & Africa Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)

Figure 72. Middle East & Africa Angiogenesis Inhibitors Sales Market Share by Application (2019-2024)

Figure 73. Egypt Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 74. South Africa Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 75. Israel Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 76. Turkey Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 77. GCC Countries Angiogenesis Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 78. Manufacturing Cost Structure Analysis of Angiogenesis Inhibitors in 2023

Figure 79. Manufacturing Process Analysis of Angiogenesis Inhibitors

Figure 80. Industry Chain Structure of Angiogenesis Inhibitors

Figure 81. Channels of Distribution

Figure 82. Global Angiogenesis Inhibitors Sales Market Forecast by Region (2025-2030)

Figure 83. Global Angiogenesis Inhibitors Revenue Market Share Forecast by Region (2025-2030)

Figure 84. Global Angiogenesis Inhibitors Sales Market Share Forecast by Type (2025-2030)

Figure 85. Global Angiogenesis Inhibitors Revenue Market Share Forecast by Type (2025-2030)

Figure 86. Global Angiogenesis Inhibitors Sales Market Share Forecast by Application (2025-2030)

Figure 87. Global Angiogenesis Inhibitors Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Angiogenesis Inhibitors Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G847FC256034EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G847FC256034EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970